Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: Analysis of the VISTA trial

  1. Richardson, P.G.
  2. Schlag, R.
  3. Khuageva, N.
  4. Dimopoulos, M.
  5. Shpilberg, O.
  6. Kropff, M.
  7. Vekemans, M.-C.
  8. Petrucci, M.T.
  9. Rossiev, V.
  10. Hou, J.
  11. Robak, T.
  12. Mateos, M.-V.
  13. Anderson, K.
  14. Esseltine, D.-L.
  15. Cakana, A.
  16. Liu, K.
  17. Deraedt, W.
  18. van de Velde, H.
  19. San Miguel, J.F.
Revue:
British Journal of Haematology

ISSN: 0007-1048,  1365-2141

Année de publication: 2011

Volumen: 153

Número: 2

Pages: 212-221

Type: Article

DOI: 10.1111/J.1365-2141.2011.08569.X GOOGLE SCHOLAR lock_openAccès ouvert editor

Objectifs de Développement Durable